Dagstuhl Reports : Volume 1, Issue 2, February 2011

Online Privacy: Towards Informational Self-Determination on the Internet (Dagstuhl Perspectives Workshop 11061) : Simone Fischer-Hübner, Chris Hoofnagle, Kai Rannenberg, Michael Waidner, Ioannis Krontiris and Michael Marhöfer Self-Repairing Programs (Dagstuhl Seminar 11062) : Mauro Pezzé, Martin C. Rinard, Westley Weimer and Andreas Zeller Theory and Applications of Graph Searching Problems (Dagstuhl Seminar 11071) : Fedor V. Fomin, Pierre Fraigniaud, Stephan Kreutzer and Dimitrios M. Thilikos Combinatorial and Algorithmic Aspects of Sequence Processing (Dagstuhl Seminar 11081) : Maxime Crochemore, Lila Kari, Mehryar Mohri and Dirk Nowotka Packing and Scheduling Algorithms for Information and Communication Services (Dagstuhl Seminar 11091) Klaus Jansen, Claire Mathieu, Hadas Shachnai and Neal E. Youn

Computational Visualistics: Dealing with Pictures in Computer Science

Building blocks from many disciplines have to be integrated into a general science of images. Computational visualistics has been formed as a contributing field embracing all aspects of dealing with images computationally. Two basic concepts of computer science are introduced. Applied to the concept "image", they determine the methodological core of computational visualistics. As the contribution of computer science to the subject of image theory, interactive pictures are examined. Finally, relations to other "image sciences" are sketched. * * * Bausteine vieler Disziplinen müssen in eine allgemeine Bildwissenschaft integriert werden. Als Beitrag aus der Informatik versteht sich die Computervisualistik, die alle Aspekte rechnergestützten Umgangs mit Bildern umfaßt. Zwei Grundbegriffe der Informatik werden vorgestellt und bestimmen, auf den Begriff "Bild" angewendet, den methodologischen Kern der Computervisualistik. Als Beitrag der Informatik zum Gegenstand der Bildtheorie werden interaktive Bilder betrachtet. Schließlich werden die Beziehungen zu anderen "Bildwissenschaften" kurz umrissen

A Riemannian View on Shape Optimization

Shape optimization based on the shape calculus is numerically mostly performed by means of steepest descent methods. This paper provides a novel framework to analyze shape-Newton optimization methods by exploiting a Riemannian perspective. A Riemannian shape Hessian is defined yielding often sought properties like symmetry and quadratic convergence for Newton optimization methods.Comment: 15 pages, 1 figure, 1 table. Forschungsbericht / Universit\"at Trier, Mathematik, Informatik 2012,

Mitteilungen : Amtsblatt der BTU Cottbus, 2012,10 (22.02.2012)

Erste Satzung zur Änderung der Prüfungs- und Studienordnung des Master-Studienganges Informatik vom 19. Dezember 2011 Neubekanntmachung: Prüfungs- und Studienordnung des Master-Studienganges Informatik vom 16. Februar 2012 (Korrigierte Fassung) (siehe AMbl 25/2017

Mitteilungsblatt / Hochschule Lausitz (FH), Nr. 179 (24.08.2009)

Änderung zum Prüfungsausschuss für die Studiengänge: Technische Informatik (Diplom), Informatik (Diplom, Bachelor und Master), Wirtschaftsingenieurwesen (Diplom, Bachelor und Master), Maschinenbau (Diplom, Bachelor und Master), Elektrotechnik (Diplom und Bachelor), Technische Informatik und Kommunikationstechnik (Bachelor und Master), Physiotherapie dual (Bachelor), Medizinische Technik (Bachelor), Kommunikations- und Elektrotechnik (Bachelor und Master), Systems Engineering (Master

Counterexamples to simulation in non-deterministic call-by-need lambda-calculi with letrec

This note shows that in non-deterministic extended lambda calculi with letrec, the tool of applicative (bi)simulation is in general not usable for contextual equivalence, by giving a counterexample adapted from data flow analysis. It also shown that there is a flaw in a lemma and a theorem concerning finite simulation in a conference paper by the first two authors

Embedded Program Annotations for WCET Analysis

We present __builtin_ais_annot(), a user-friendly, versatile way to transfer annotations (also known as flow facts) written on the source code level to the machine code level. To do so, we couple two tools often used during the development of safety-critical hard real-time systems, the formally verified C compiler CompCert and the static WCET analyzer aiT. CompCert stores the AIS annotations given via __builtin_ais_annot() in a special section of the ELF binary, which can later be extracted automatically by aiT

Prüfungsordnung für den Masterstudiengang Mathematik an der Universität Paderborn : vom 22. Oktober 2008

Fakultät für Elektrotechnik, Informatik und Mathemati

Satzung zur Änderung der Prüfungsordnung für den Bachelorstudiengang Elektrotechnik an der Universität Paderborn : vom 14. März 2008

Fakultät für Elektrotechnik, Informatik und Mathemati

Market uptake of pegylated interferons for the treatment of hepatitis C in Europe : meeting abstract

Introduction and Objectives Hepatitis C virus (HCV) infection is a leading cause of chronic liver disease with life threatening sequelae such as end-stage liver cirrhosis and liver cancer. It is estimated that the infection annually causes about 86,000 deaths, 1.2 million disability adjusted life years (DALYs), and ¼ of the liver transplants in the WHO European region. Presently, only antiviral drugs can prevent the progression to severe liver disease. Pegylated interferons combined with ribavirin are considered as current state-of-the-art treatment. Objective of this investigation was to assess the market uptake of these drugs across Europe in order to find out whether there is unequal access to optimised therapy. Material and Methods We used IMS launch and sales data (April 2000 to December 2005) for peginterferons and ribavirin for 21 countries of the WHO European region. Market uptake was investigated by comparing the development of country-specific sales rates. For market access analysis, we converted sales figures into numbers of treated patients and related those to country-specific hepatitis C prevalence. To convert sales figures into patient figures, the amount of active pharmaceutical ingredients (API) sold was divided by average total patient doses (ATPD), derived by a probability tree-based calculation algorithm accounting for genotype distribution, early stopping rules, body weight, unscheduled treatment stops and dose reductions Ntotal=APIPegIFNalpha-2a/ATPDPegIFNalpha-2a+APIPegIFN&alpha-2b/ATPDPegIFNalpha-2b For more concise result presentation the 21 included countries were aggregated into four categories: 1. EU founding members (1957): Belgium, France, Germany, Italy and Netherlands; 2. Countries joining EU before 2000: Austria (1995), Denmark (1973), Finland (1995), Greece (1981), Republic of Ireland (1973), Spain (1986), Sweden and UK (1973) 3. Countries joining EU after 2000: Czech Republic (2004), Hungary (2004), Poland (2004) and Romania (2007); 4. EU non-member states: Norway, Russia, Switzerland and Turkey. Results Market launch and market uptake of the investigated drugs differed considerably across countries. The earliest, most rapid and highest increases in sales rates were observed in the EU founding member states, followed by countries that joined the EU before 2000, countries that joined the EU after 2000, and EU non-member states. Most new EU member states showed a noticeable increase in sales after joining the EU. Market access analysis yielded that until end of 2005, about 308 000 patients were treated with peginterferon in the 21 countries. Treatment rates differed across Europe. The number of patients ever treated with peginterferon per 100 prevalent cases ranged from 16 in France to less than one in Romania, Poland, Greece and Russia. Discussion Peginterferon market uptake and prevalence adjusted treatment rates were found to vary considerably across 21 countries in the WHO European region suggesting unequal access to optimised therapy. Poor market access was especially common in low-resource countries. Besides budget restrictions, national surveillance and prevention policy should be considered as explanations for market access variation. Although our results allowed for the ranking of countries in order of market access, no final conclusions on over- or undertreatment can be drawn, because the number of patients who really require antiviral treatment is unknown. Further research based on pan-European decision models is recommended to determine the fraction of not yet successfully treated but treatable patients among those ever diagnosed with HCV. ..